Dilantin-associated lymphadenopathy. Spectrum of histopathologic patterns

Area of Science:

• Pathology
• Toxicology
• Oncology

Background:

• Dilantin (hydantoin) therapy is linked to lymphadenopathy, but details are scarce.
• Previous reports often lack comprehensive pathologic information.

Purpose of the Study:

• To describe clinicopathologic features of Dilantin-associated lymphadenopathy.
• To confirm the heterogeneity and nonspecificity of histologic patterns.

Main Methods:

• Reviewed 25 lymph node lesions suspected of Dilantin association (1965-1991).
• Assessed histologic features and immunophenotypic data.
• Classified cases based on "operational degrees of certainty" for drug association.

Main Results:

• 15 cases showed benign histology (immunoblastic hyperplasia), 7 were non-Hodgkin's lymphoma, 3 were Hodgkin's disease.
• Lymphadenopathy developed 1 week to 30 years after starting Dilantin.
• Two cases showed progression from hyperplasia to malignant lymphoma.

Conclusions:

• Dilantin-associated lymphadenopathy exhibits diverse and nonspecific histologic patterns.
• The findings highlight the importance of considering drug-induced reactions in lymphadenopathy evaluation.
• Further research is needed to fully understand the mechanisms and long-term implications.